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A Beautiful Mind, by Sylvia Nasar. London: Faber & Faber, 
1998. ISBN 0-571-21292-1. 
The movie 'A Beautiful Mind' won Oscars for Best Picture, Best 
Director, Best Supporting Actress, and Best Screenplay. 
Hollywood typically does spectacularly badly in representing 
specialist knowledge to the movie-going public. This movie, 
which is about paranoid schizophrenia and the 
sort of mathematics it takes to win the Nobel 
Prize in Economics, did better than the poor 
average. However, it remains a Hollywood 
movie designed for a general audience. It 
fudged the core medical and mathematical 
issues for the sake of visual appeal. The 
biography that inspired the movie, however, is a 
blockbuster. It does a notably good job of 
presenting these issues to a general audience. It 
was a worthy Pulitzer Prize finalist and won the 
1998 National Book Critics Award for Biography. 
Thanks to the movie, the bookshops are 
currently stocking the biography. 
Alfred Nobel reputedly hated 
mathematicians. On his death in 1894, his 
famous will did not endow a Nobel Prize in mathematics. The 
salacious stories of sexual and professional jealousy behind this 
omission are disappointingly apocryphal. Neither, though, did 
Nobel endow a prize in 'the dismal science'. Only in 1968 did 
the Bank of Sweden controversially create the 'so-called Nobel 
Prize in Economics'. In 1950, therefore~ when the 21-year-old 
John Nash submitted his 27-page PhD thesis - the prize it was 
to win him in 1994 did not yet exist. 
The 'mathematics Nobel' is the Fields Medal, the ultimate 
distinction a mathematician can win. It is arguably harder to 
win than a Nobel. Nobels come every year but Fields Medals 
are awarded at the International Congress of Mathematicians, . 
held only every 4 years. Furthermore, strong tradition 
demands that recipients be younger than 40 years of age. Even 
Andrew Wiles, who made newspaper headlines worldwide 
when he plugged a_350-year-old gap and proved Fermat's Last 
Theorem, missed out on the Fields Medal. His 41st birthday 
crept past as he made the final corrections to his proof. 
The age restriction both encourages young researchers and 
acknowledges the shortness of a mathematician's creative life. 
Michael Rolfe, a literate engineer, is currently IT manager of the 
Department of Mathematics and Applied Mathematics at UCT. 
His interests include the history of mathematics. 
June 2002, Vol. 92, No. 6 SAMJ 
Compared with the general population, creative mathematics is 
overwhelmingly a young man's game. John von Neumann, 
polymath wunderkind of 20th century mathematics, used to say 
that 'the primary mathematical powers decline at about 
twenty-six', after which the mathematician must rely on 'a 
certain more prosaic shrewdness'. It is strikingly improbable 
that any mathematician, even the most spectacular of child 
prodigies, will produce groundbreaking work after reaching 
maturity. 
The hubristic, ambitious, super-competitive Nash 
characteristically went after big problems. As a graduate 
student at Princeton, he approached Einstein to propose a 
correction to the Theory of Relativity. The great man listened 
politely and gently suggested that the young mathematician 
should study physics first. Instead, Nash turned to Game 
Theory and dramatically extended the work of 
the god-figure von Neumann. He went on to 
solve some impressively difficult problems that 
might well have won him the Fields Medal. 
Colleague and rival John Milnor, who was 
dazzled by Nash's 'keen, beautiful, logical 
mind', wrote, 'To some, the brief paper, written 
at age 21, for which he has won a Nobel prize in 
economics, may seem like the least of his 
achievements.' Part of his latter work was 
independently duplicated, however. This 
sufficed, he suspected, to deprive him of 
recognition. At the age of 30, with no Fields 
Medal, he faced the prospect of becoming a 
mathematical geriatric. 
'It is not bearable to contemplate a brief 
distinction and burgeoning of activity ... followed by a lifetime 
of boredom,' wrote Norbert Wiener, ex-child-prodigy and 
creator of the science of cybernetics. Seeking the recognition he 
craved, Nash desperately tackled the biggest plum of all: the 
proof of the Riemann Hypothesis. He failed. It remains today 
the most important unsolved problem in mathematics. He also 
addressed a criticism of Einstein's, that quantum mechanics 
and relativity, although both well established, are incompatible. 
He made no breakthrough there, either, and Einstein's criticism 
has yet to be answered. 
The beautiful mind then wandered into paranoid 
schizophrenia. When his family could no longer cope, they 
had him committed to the health care treatments of the day. 
The maths geek who craved solitude was assigned a serial 
number and lived locked in a room with 30 to 40 other 
inmates. The beautiful mind underwent sixties-style drug 
therapy, insulin coma therapy, and electroshock - treatments 
that always lackeq convincing evidence of efficacy. By refusing 
to take antipsychotic drugs after 1970, though, Nash may have 
saved himself from tardive dyskinesia and the mental 
deadening that, when remission eventually came, would have 
barred him from the world of mathematics. Very little of this, 
or of the mathematics, comes through in the movie. The book 
is incomparably better. 
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one actually have an influence? (I'd be delighted to be proved 
wrong on this, but I would suspect that the current position in 
South Africa, for example, where there is gross stigmatisation of 
mental illness, with abysmal under funding of psychiatric 
services and of psychiatric research, is unlikely to improve in 
the near future.) 
There is also the risk of insufficient emphasis being placed on 
the evidence-based approach. This volume certainly attempts 
to be scientific, referring to some evidence e.g. p109 and 
emphasising the need for further research e.g. p112. But is this 
enough? Any new medication that comes to the market is 
required to undergo rigorous controlled trials in order to 
demonstrate efficacy and safety. Surely at least the same degree 
of rigor is necessary before new socio-political policies, which 
may require enormous resources and have the potential for 
inflicting tremendous harm, are blithely introduced. The 
Cochrane Collaboration is not referenced in the index; a notable 
omission given the valuable contribution of this important 
effort to emphasise the value of an evidence-based approach 
towards assessing pharmacological treatments and other kinds 
of intervention. How good, really, is the evidence behind the 
proposals in this report? 
On this point, I noted at least some points in the report that 
flew in the face of the evidence-base - including the suggestion 
that PTSD is culture specific, overdiagnosed or 'invented'; the 
assertion that antidepressants are for depression while 
anxiolytics are for anxiety; the argument that new generation 
antipsychotics are not more effective than older ones; and the 
minimisation of the value of pharmacotherapy in attention 
deficit disorder. 
Another risk relates to the WHO's particular interest, for · 
example, in matters such as government policy, 
notwithstanding that many of the psychiatric advances noted 
here have been driven by the private sector. The resources and 
power of the pharmaceuticals are enormous; the report ignores 
this rather than thinking through the crucial question of how 
best to engage pharmaceuticals to achieve its own objectives. It 
fails to debate fully contentious issues in mental health policy 
such as prescription by psychologists, working with traditional 
healers, or the prevention of and response to social violence. It 
predictably lauds the value of treatment in primary care but 
arguably fails to tackle the real conceptual and practical 
difficulties this involves. 
This report will be a valuable resource for those fighting the 
good fight to promote awareness of mental disorders and to 
prevent stigmatisation of those suffering from these most 
disabling of medical conditions. In serving that purpose it is a 
useful addition to the literature (although everything in it can 
likely be found in other sources, the imprimatur of the WHO is 
perhaps uniquely valuable). Whether this volume itself will in 
fact significantly advance this good fight, is another matter. 
Dan Stein 
NEUROPATHIC PAIN 
Pathophysiology and Treatment. Progress in Pain Research and 
Management Volume 21. Edited by Per Hansson, Howard Fields, 
Ramond Hill and Paolo Marchettini. Pp x +277. US$79. IASP Press. 
2001. ISBN 0-931-092-38-8. 
The management of chronic pain remains a difficult 
challenge. Our lack of understanding of the pathophysiology of 
chronic painful conditions has led to our inability to develop 
new, more effective treatments for these conditions. 
An enormous amount of pain research has been undertaken 
over the last decade or so, and this book aims to summarise the 
progress that has.been made. Each chapter examines a 
particular aspect of neuropathic pain. In each, an expert reviews 
the evidence and explains the current controversies and lines of 
future research. The chapters are well referenced and the 
references are up to date. 
This is not a book for someone seeking an introduction to the 
subject. It is aimed at an audience wishing to keep up with the 
latest developments in the field. In this respect it succeeds 
admirably and I would recommend this book to anyone dealing 
with chronic pain patients. However, with a list price of $80 for 
a relatively slim volume, it is hardly a bargain. 
Stephen Rous 
ACUTE AND PROCEDURE PAIN IN 
INFANTS AND CHILDREN 
Edited by A Finley and Patrick McGrath. Pp. x + 183. US$70. !ASP 
Press. ISBN 0-931092-39-6. 
This book has an unusual approach to the subject of 
paediatric pain in that it touches on basic science, clinical 
practice and ethical issues. The editors are well-known 
international experts in the field, as are the contributing 
authors, and this makes for a powerful combination in 
providing this reference on paediatric pain. It is published 
under the auspices of the International Association for the 
Study of Pain and is reasonably priced at US$70. 
The articles are carefully and thoroughly researched, well 
written and referenced, and form a cohesive collation of subject 
matter. A theme evident throughout the book is the awareness 
of how poorly pain in children of all ages has been managed in 
the past, and how this is currently being addressed. 
Understanding basic sciences, the neurobiology of pain and DD 
being informed of all modalities available for improving pain 
relief, improve the management of the child for painful 
procedures and postoperative pain, not to mention the 
appropriate treatment of chronic pain. 
Regional and local anaesthesia is becoming increasingly 
popular, and the chapter by Woolf has interesting perspectives 
